Protagenic Therapeutics Inc (NASDAQ: PTIX) has experienced a rise in its stock price by 11.66% compared to its previous closing price of $3.43. However, the company has seen a gain of 8.19% in its stock price over the last five trading days. accessnewswire.com reported 2025-05-21 that NEW YORK, NY / ACCESS Newswire / May 21, 2025 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX) (the “Company”) announced today that warrant exchanges and exercises over the last four trading days have generated $3.1 million in cash. The proceeds will fund working-capital needs and advance the Company’s peptide-based drug candidates for stress-related and central-nervous-system disorders.
Is It Worth Investing in Protagenic Therapeutics Inc (NASDAQ: PTIX) Right Now?
Analysts have varying opinions on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for PTIX is 0.80M and currently, short sellers hold a 4.08% of that float. On July 10, 2025, PTIX’s average trading volume was 1.91M shares.
PTIX’s Market Performance
PTIX stock saw an increase of 8.19% in the past week, with a monthly gain of 5.80% and a quarterly increase of -14.05%. The volatility ratio for the week is 6.94%, and the volatility levels for the last 30 days are 7.15% for Protagenic Therapeutics Inc (PTIX). The simple moving average for the past 20 days is 7.80% for PTIX’s stock, with a -33.06% simple moving average for the past 200 days.
PTIX Trading at 0.53% from the 50-Day Moving Average
After a stumble in the market that brought PTIX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -75.35% of loss for the given period.
Stock Fundamentals for PTIX
The total capital return value is set at 61.25. Equity return is now at value -512.79, with -293.85 for asset returns.
Currently, EBITDA for the company is -5.47 million with net debt to EBITDA at 0.17. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.86.
Conclusion
To wrap up, the performance of Protagenic Therapeutics Inc (PTIX) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
